Search results
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
Investor's Business Daily· 2 years agoPfizer's nearly $7 billion takeover of Arena Pharmaceuticals looked prescient Tuesday after the...
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
Motley Fool via Yahoo Finance· 1 month agoSome investors might remember the obesity drugs developed by Arena Pharmaceuticals and Vivus...
Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies
Benzinga via Yahoo Finance· 2 years agoPfizer Inc (NYSE: PFE) has announced detailed results from two pivotal studies from ELEVATE UC Phase...
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
Motley Fool· 1 year agoPfizer (NYSE: PFE) has been a company on a mission, looking to restock its pipeline with growth...
Pfizer ulcerative colitis drug leads to remission in a third of patients -study
Reuters via Yahoo News· 2 years agoNearly one third of patients with ulcerative colitis who received an experimental Pfizer Inc drug in...
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
Motley Fool· 5 months agoPfizer's (NYSE: PFE) stock performance has been disappointing this year (down 38%). For example,...
2 Incredible Growth Stocks That Are Screaming Buys for 2024
Motley Fool via Yahoo Finance· 3 months agoThe new year is here, and for many, it's a fresh opportunity to set financial goals and find fresh...
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Q4 2022 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Q4 2022 Earnings Call Transcript March 2, 2023...
Is Pfizer Stock a Millionaire Maker?
Motley Fool via Yahoo Finance· 2 months agoThe stock market is at record levels these days, but one company that isn't reflecting that optimism is Pfizer (NYSE: PFE). Shares of the pharma giant...
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
Motley Fool· 1 year agoLast December, Pfizer (NYSE: PFE) essentially out-licensed its tumor necrosis factor-like ligand 1A...
